# Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.

> **NCT07730151** · PHASE2 · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate
- Prostate Cancer Patients

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** docetaxel
- **DRUG:** ADT

## Key facts

- **NCT ID:** NCT07730151
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730151, "Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07730151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*